Bristol-Myers Squibb is the first major drug firm to forgo advertising new drugs to consumers in a product’s first year on the market
I applaud the move. Not quite a ban on DTC advertising, but it’s a start.
ADVERTISEMENT
More in Uncategorized
Past Week
-
Alex Pretti: a physician’s open letter defending his legacy
-
The hidden costs of the physician non-clinical career transition
-
The elephant in the room: Why physician burnout is a relationship problem
-
ADHD and cannabis use: Navigating the diagnostic challenge
-
Why private equity is betting on employer DPC over retail
-
Leading with love: a physician’s guide to clarity and compassion
-
Past 6 Months
-
Physician on-call compensation: the unpaid labor driving burnout
-
How environmental justice and health disparities connect to climate change
-
Will AI replace primary care physicians?
-
A physician father on the Dobbs decision and reproductive rights
-
What is the minority tax in medicine?
-
Why the U.S. health care system is failing patients and physicians
-
Recent Posts
-
Waking up at 4 a.m. is not required for success [PODCAST]
-
Medical education’s blind spot: the cost of diagnostic testing
-
Disruptive physician labeling: a symptom of systemic burnout
-
Medicine changed me by subtraction: a physician’s evolution
-
Genetic mutations and racial disparities in leukemia survival
-
The hidden costs of the physician non-clinical career transition
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
